Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Aug 2025 | FROM AKERO THERAPEUTICS

Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Mazen Noureddin, Juan P Frias, Guy Neff, K Jean Lucas, Cynthia Behling, Pierre Bedossa, Julie Dubourg, Doreen Chan, Mark Burch, Erica Fong, Brittany de Temple, Matt Minerva, Kim Barrett, Reshma Shringarpure, Erik J Tillman, Tim Rolph, Andrew Cheng, Kitty Yale The Lancet

Aug 2025 | FROM AKERO THERAPEUTICS

Efruxifermin improved fibrosis due to MASH in participants with F2/F3 fibrosis or compensated cirrhosis due to MASH: results of two 96-week, randomized, double-blind, placebo-controlled, phase 2b trials

Arun Sanyal, Naga P Chalasani, Mary E Rinella, Doreen Chan, Erik Tillman, Erica Fong, Arian Zari, Brittany de Temple, Mark Burch, Reshma Shringarpure, Meena Jain, Tim Rolph, Andrew Cheng, Kitty Yale, Mazen Noureddin INASL 2025

Jul 2025 | FROM AKERO THERAPEUTICS

A newly revealed signaling pathway may explain the conundrum of how FGF21 simultaneously increases insulin sensitivity and autophagy

Timothy Rolph, Morris J. Birnbaum Journal of Hepatology

May 2025 | FROM AKERO THERAPEUTICS

qFibrosis enables earlier detection of fibrosis response in Efruxifermin-treated patients with F2-F3 MASH in 96-week HARMONY study

Jörn M. Schattenberg, Dean Tai, Elaine Chng, Yukti Choudhury, Galvin Gan, Cynthia Behling, Pierre Bedossa, Doreen Chan, Jimmie Zhang, Erica Fong, Brittany de Temple, Matthew Minerva, Mark Burch, Kimberly Barrett, Reshma Shringarpure, Erik Tillman, Tim Rolph, Andrew Cheng, Kitty Yale, Mazen Noureddin EASL 2025

May 2025 | FROM AKERO THERAPEUTICS

Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, double-blind, placebo-controlled, phase 2b trial (SYMMETRY)

Mazen Noureddin, Mary E Rinella, Naga P Chalasani, Guy Neff, K Jean Lucas, Manuel E Rodriguez, Madhavi Rudraraju, Rashmee Patil, Cynthia Behling, Mark Burch, Doreen Chan, Erik J Tillman, Arian Zari BS, Brittany de Temple, Reshma Shringarpure, Meena Jain, Tim Rolph, Andrew Cheng, Kitty Yale EASL 2025

May 2025 | FROM AKERO THERAPEUTICS

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

Mazen Noureddin, Mary E Rinella, Naga P Chalasani, Guy Neff, K Jean Lucas, Manuel E Rodriguez, Madhavi Rudraraju, Rashmee Patil, Cynthia Behling, Mark Burch, Doreen Chan, Erik J Tillman, Arian Zari BS, Brittany de Temple, Reshma Shringarpure, Meena Jain, Tim Rolph, Andrew Cheng, Kitty Yale New England Journal of Medicine

Jan 2025 | FROM AKERO THERAPEUTICS

Pleiotropic effects of FGF21 in liver, brain, and adipose tissue

Tim Rolph MASH-TAG 2025

Dec 2024 | FROM AKERO THERAPEUTICS

Improvement of liver fibrosis in efruxifermin-treated patients with MASH: correlation between conventional histopathology, AI-based digital histopathology, and non-invasive biomarkers of fibrosis

Erik J Tillman, Doreen Chan, Reshma Shringarpure, Yukti Choudhury, Elaine Chng, Dean Tai, Kitty Yale, Tim Rolph Keystone Symposia Fibrosis: Inflammation, Drivers, and Therapeutic Resolution

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.

View Our Pipeline